Key points are not available for this paper at this time.
Anaplastic thyroid cancer (ATC) is a rapidly growing, lethal malignancy posing challenges for timely diagnosis and treatment, resulting in a median survival of 5 months. Currently, effective neoadjuvant therapy has not been established for ATC and other advanced thyroid cancers, although both targeted therapy and immunotherapy are being actively investigated for these cases. This case highlights the transformative impact of neoadjuvant therapy with tyrosine kinase inhibitors (TKI) on an ATC, suggesting of potential implications of this treatment approach.
Kuruppu et al. (Wed,) studied this question.